Pacific Biosciences announced the first customer shipments of Revio long-read sequencing systems will commence on March 8. The Revio system features advances in SMRT Cell design, compute, and system architecture. With the Revio system, researchers will be able to scale their interrogation of the full genome in the same run. The Broad Institute of MIT and Harvard has ordered ten Revio systems to scale long-read sequencing for population sequencing initiatives. Additional Revio systems will also be shipped to customers in China, Japan, Korea, Netherlands, and Sweden. PacBio announced orders of 76 Revio systems in the quarter ended December 31, 2022. PacBio expects to ship at least 25 Revio systems during Q1 and will continue to scale throughout the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PACB:
- Pacific Biosciences price target lowered to $10 from $11 at Piper Sandler
- PacBio Announces Fourth Quarter and Fiscal Year 2022 Financial Results
- Pacific Biosciences reports Q4 adjusted EPS (35c), consensus (36c)
- Pac Bio options imply 4.4% move in share price post-earnings
- Pacific Biosciences initiated with a Neutral at UBS